Acinetobacter Species Infections among Navy and Marine Corps Beneficiaries: 2014 Annual Report

Abstract

Abstract : Since the early 2000s, health professionals are increasingly concerned about Acinetobacter species infections due to demonstrated ability to develop resistance to multiple antibiotics, limiting treatment options. In 2014, Acinetobacter incidence was 3.2 and 4.7 per 100,000 persons per year in the Department of the Navy (DON) and the Department of Defense (DOD), respectively, both of which were a slight increase from 2013. Active duty Marines had a higher burden than that of any other service members. Acinetobacter species, not otherwise specified, was the most common etiologic agent in 2014. In the DON, a decrease in the overall burden of resistance was observed, as well as an overall decrease in the severity of resistance seen. For non-multidrug-resistant (MDR) cases in the DON and DOD, providers often prescribed trimethoprim/sulfamethoxazole, consistent with 2012 observations. For multidrug-resistant cases in 2014, DON providers most commonly prescribed cefazolin; DOD providers most commonly prescribed ciprofloxacin and trimethoprim/sulfamethoxazole for these cases. Although slightly different from 2013, 2014 prescribing patterns were consistent with recommendations. Among DON beneficiaries organisms were most susceptible to gentamicin while least susceptible to ceftriaxone. Among DOD beneficiaries, organisms were most susceptible to ampicillin/sulbactam and least susceptible to nitrofurantoin, similar to past observations for the DON and DOD. An overall increase in susceptibility for most antibiotics was identified.